FRANKFURT, March 9 (Reuters) - Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...

A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...

March 9 (Reuters) - Bristol Myers Squibb on Monday said its experimental cancer drug met the main goal of a late-stage study.

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

Roche’s shares tumbled nearly 5% on news that a key pillar in the five-pronged clinical plan for the breast cancer asset ...

Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

Many therapeutic molecules used in cancer treatments are highly toxic, often harming healthy tissues and causing significant ...

Ipsen found cases of secondary malignancies in a confirmatory study of Tavzerik, a medicine it got in a purchase of Epizyme ...

Roche said the late-stage trial did not provide reliable evidence that ​the drug's use in combination with Pfizer's Ibrance ...